The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system

• Váldodahkkit: Wei Wei (Dahkki), Liang Huang (Dahkki), Yingtao Bai (Dahkki), En Chang (Dahkki), Jinfeng Liu (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

BackgroundOseltamivir and baloxavir marboxil are the two primary oral drugs approved by the Food and Drug Administration (FDA) for treating influenza. Limited real-world evidence exists on their adverse events in children. The purpose of this study was to explore the adverse event (AE) profiles of o...